INITIATING TREATMENT WITH MAYZENT®—A ONCE-DAILY ORAL1
INITIATING TREATMENT WITH MAYZENT®—A ONCE-DAILY ORAL1
Assessments recommended for all patients

BLOOD TESTS
-
CBC
-
CYP2C9 genotype testing*
-
VZV antibody serology
-
LFT (transaminase & bilirubin)

AN OPHTHALMIC EVALUATION
-
Evaluation of the fundus, including the macula
-
If there is any change in vision during treatment, a follow-up evaluation is recommended

AN ECG TEST
-
ECG to determine whether an FDO is recommended
*Genotype testing is required to determine the appropriate maintenance dose.
Assessments recommended for all patients

BLOOD TESTS
-
CBC
-
CYP2C9 genotype testing*
-
VZV antibody serology
-
LFT (transaminase & bilirubin)

AN OPHTHALMIC EVALUATION
-
Evaluation of the fundus, including the macula
-
If there is any change in vision during treatment, a follow-up evaluation is recommended

AN ECG TEST
-
ECG to determine whether an FDO is recommended
*Genotype testing is required to determine the appropriate maintenance dose.
First-dose observation for patients with preexisting
cardiac conditions
An FDO of 6 hours is needed for patients with:
-
Sinus bradycardia (HR <55 BPM)
-
First- or second-degree Mobitz type I AV block
-
A history of myocardial infarction or heart failure
-
Monitoring should continue for 6 hours after the first dose to evaluate for signs and symptoms of bradycardia
-
An ECG should be conducted at the end of the observation period
First-dose observation for patients with preexisting
cardiac conditions
An FDO of 6 hours is needed for patients with:
-
Sinus bradycardia (HR <55 BPM)
-
First- or second-degree Mobitz type I AV block
-
A history of myocardial infarction or heart failure
-
Monitoring should continue for 6 hours after the first dose to evaluate for signs and symptoms of bradycardia
-
An ECG should be conducted at the end of the observation period
MOST PATIENTS WILL NOT REQUIRE AN FDO1
MOST PATIENTS WILL NOT
REQUIRE AN FDO1
Regular ophthalmic follow-ups for patients with a history
of diabetes or uveitis1
Regular follow-up ophthalmic
evaluations are recommended
Regular ophthalmic follow-ups for patients with a history
of diabetes or uveitis1
Regular follow-up ophthalmic
evaluations are recommended
A 4- OR 5-DAY TITRATION REGIMEN HELPS PATIENTS REACH THEIR MAINTENANCE DOSE
MAYZENT is a once-daily treatment with a recommended dosage of 1 mg or 2 mg,
based on the results of genotype testing


Before opening, MAYZENT 0.25-mg and 2-mg tablets should be stored in a refrigerator between 36°F to 46°F (2°C to 8°C).
Dosing and Administration Guide
DOWNLOADAdditional considerations1
-
If treatment reinitiation is required, repeat assessments and FDO as needed
-
For patients who are taking antineoplastic, immunosuppressive, or immune-modulating therapies, or who have previously used these types of medications, consider the potential unintended additive immunosuppressive effects before initiating treatment with MAYZENT
-
Determine whether patients are taking drugs that could slow heart rate or AV conduction
-
Avoid the administration of live attenuated vaccines during treatment, and for 4 weeks after stopping treatment
-
For patients with a CYP2C9*1/*3 or *2/*3 genotype, the recommended maintenance dosage is 1 mg daily starting on Day 5. MAYZENT should not be used in patients with a CYP2C9*3/*3 genotype
GET PATIENTS STARTED ON MAYZENT®
AV=atrioventricular; BPM=beats per minute; CBC=complete blood count; ECG=electrocardiogram; FDO=first-dose observation; HR=heart rate; LFT=liver function test; VZV=varicella zoster virus.
Reference: 1. Mayzent [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; March 2019.